Implementing a Cost-Effective Cure for Batch and Sequence Management - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Implementing a Cost-Effective Cure for Batch and Sequence Management

Equipment and Processing Report

Implementing a Cost-Effective Cure for Batch and Sequence Management

Q. Our company wants to upgrade its single-product semiworks facility to a midscale production facility capable of producing a variety of regulated products. How can we implement a flexible solution without increasing our project budget?

A. Other companies in similar situations have implemented flexible, cost-effective solutions. For example, a small-molecule API manufacturer wanted to upgrade its single-product semiworks facility to a midscale production facility capable of producing a variety of products. The company needed a scalable solution that would meet regulatory requirements and increased security demands for producing regulated materials and controlled substances. Unfortunately, the existing control infrastructure was based on a hard-coded control system from the 1990s that limited its ability to quickly and easily adjust programming and production, which was a requirement for the company as it moved the facility to multiproduct production. The company worked with its automation partner to identify the best control solution.

Some modern control systems allow users to program batch sequencing and use the controller independently of application servers and software. This independent function allows companies to avoid costly, engineering-intensive custom code or additional server infrastructure associated with large-scale batch solutions. Software is available to configure recipes and formulas directly in the controller without requiring code changes to the system, which helps streamline the implementation of approved changes.

Companies today would like to reduce their use of manual, paper-based batch sheets for detailed processing instructions, but API manufacturing processes often require a high level of detail. In this company’s process, for example, removing a kill solution that deactivates a volatile chemical too soon could significantly impact the entire process. Automated solutions that take these detailed instructions into account can be embedded directly into the control system, which can improve the quality and consistency of APIs and avoid the delays that naturally occur during manual operations.

—John Párraga, global process technical consultant at Rockwell Automation.

If you have a problem with your equipment or process, an industry expert may have the solution. Please send your question to Jennifer Markarian, editor of Equipment and Processing Report, and we may be able to provide an answer in a future issue. All questions will remain anonymous.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Equipment and Processing Report,
Click here